Innovations in Cancer Care and Research
Dr. Laurie H. Glimcher, MD, became the president and CEO of Dana-Farber Cancer Institute last fall. In one of her first public addresses since taking the helm, Dr. Glimcher will discuss the economic impact of Boston’s teaching hospitals, exciting progress in cancer research and care, how collaboration with industry helps facilitate the work, and the potential impact of current health policy debates.
Dr. Glimcher was was previously the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College in New York City, New York, where she is also Professor of Medicine. Dr. Glimcher is widely considered to be one of the world leaders in understanding cellular differentiation pathways in lymphocytes and has made seminal discoveries of key transcription factors that drive lineage commitment and activation in the immune system. Most recently, she has discovered a critical signaling pathway in both tumor cells and in host immune responses, translating her basic discoveries in the control of immune cell differentiation into a new approach to cancer immunotherapy.